Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 698NCT00413049
• EFFORTIndependent statistical analysis of Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 43NCT03011775
• eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients: Complete Statistical AnalysisIndependent statistical analysis of eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 216NCT02458690
• EinsteinChoiceComplete statistical analysis of the EinsteinChoice phase 3 trial of reduced-dose rivaroxaban for long-term prevention of recurrent symptomatic venous thromboembolism, including trial design, endpoints, hazard ratios, confidence intervals, safety, and statistical interpretation.Phase 3Results postedn = 3,365NCT02064439
• ELANIndependent statistical analysis of the ELAN randomized trial comparing early versus late initiation of direct oral anticoagulants in patients with ischaemic stroke and atrial fibrillation.Phase NAn = 2,013NCT03148457
• EMMAIndependent statistical analysis of Extracellular Matrix Marker of Arrhythmia Risk (EMMA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00376532).Phase NAResults postedn = 63NCT00376532
• EMMYIndependent statistical analysis of Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 476NCT03087773
• EMPACT-MIIndependent statistical analysis of EMPACT-MI, the randomized, placebo-controlled phase 3 trial of empagliflozin 10 mg after myocardial infarction: covariate-adjusted Cox hazard ratio for heart failure hospitalisation or death, negative binomial rate ratios…Phase 3Results postedn = 6,522NCT04509674
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): Complete Statistical AnalysisIndependent statistical analysis of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 5,988NCT03057951
• EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…Phase 3Results postedn = 3,730NCT03057977
• EMPOWER-MomIndependent statistical analysis of Postpartum Weight Loss for Women at Elevated Cardiovascular Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04914819).Phase NAResults postedn = 89NCT04914819
• ENCHANTEDIndependent statistical analysis of the ENCHANTED phase 3 factorial trial of low-dose versus standard-dose rtPA and intensive versus standard blood-pressure management in acute ischemic stroke.Phase 3n = 4,587NCT01422616
• ENCORE-VTIndependent statistical analysis of Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 19NCT02919618
• ENDEAVORIndependent statistical analysis of Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 929NCT01568866
• Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts: Complete Statistical AnalysisIndependent statistical analysis of Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583050).Phase NAResults postedn = 1,366NCT00583050
• ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.Phase 3Results postedn = 21,105NCT00781391
• Enhancing Caregiver Support for Heart Failure Patients: the CarePartner Study: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Caregiver Support for Heart Failure Patients: the CarePartner Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00555360).Phase NAResults postedn = 372NCT00555360
• Enhancing Plasticity in Stroke Patients With Severe Motor Deficit: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Plasticity in Stroke Patients With Severe Motor Deficit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02633215).Phase NAResults postedn = 36NCT02633215
• EnligHTN-IVIndependent statistical analysis of EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 4NCT01903187
• ENSURE-AFA detailed statistical analysis of the ENSURE-AF phase 3 trial comparing edoxaban with warfarin in patients undergoing cardioversion for nonvalvular atrial fibrillation, including endpoint definitions, odds-ratio interpretation, confidence intervals, analysis populations, and…Phase 3Results postedn = 2,199NCT02072434
• Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 66NCT01796470
• ENTRUST-AF-PCIIndependent statistical analysis of Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 1,506NCT02866175
• EPITHETIndependent statistical analysis of the EPITHET phase 2 trial evaluating alteplase t-PA in acute stroke, including design, endpoints, planned methodology, and statistical interpretation.Phase 2n = 100NCT00238537
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 31NCT00400686
• Ertugliflozin: Cardioprotective Effects on Epicardial Fat: Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin: Cardioprotective Effects on Epicardial Fat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04167761).Phase EARLY_1Results postedn = 61NCT04167761
• Esmolol for Treatment of Perioperative Tachycardia: Complete Statistical AnalysisIndependent statistical analysis of Esmolol for Treatment of Perioperative Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01208402).Phase 3Results postedn = 76NCT01208402
• Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 70NCT01212874
• EU RCTIndependent statistical analysis of ILLUMENATE EU Randomized Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01858363).Phase NAResults postedn = 294NCT01858363
• EUROMAXComplete statistical analysis of the EUROMAX phase 3 trial of bivalirudin versus standard-of-care heparins with optional GPI in acute coronary syndrome, including trial design, the primary binary endpoint, risk ratio, confidence interval,…Phase 3Results postedn = 2,198NCT01087723
• EV ICDIndependent statistical analysis of Extravascular ICD Pivotal Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04060680).Phase NAResults postedn = 393NCT04060680
• EVA-3SAn independent statistical analysis of EVA-3S, a phase 3 randomized trial concerning carotid angioplasty and stenting with cerebral protection in patients with severe symptomatic carotid stenosis.Phase 3n = 900NCT00190398
• Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 25NCT00540436
• Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 20NCT04087122
• Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 39NCT04098172
• Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 11NCT02228460
• Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 33NCT00847730
• Evaluation of a New Cardiac Biomarker Assay: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a New Cardiac Biomarker Assay: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01608100).Phase 3Results postedn = 1,101NCT01608100
• Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 51NCT06063603
• Evaluation of Atorvastatin on Atherosclerosis Composition: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Atorvastatin on Atherosclerosis Composition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576576).Phase NAResults postedn = 27NCT00576576
• Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 18NCT01598740
• Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03169062).Phase NAResults postedn = 10NCT03169062
• Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 60NCT01635881
• Evaluation of Diet and Sleep in Vascular Health: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Diet and Sleep in Vascular Health: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 11NCT04990973
• Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 2,230NCT02666664
• Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 100NCT01926977
• Evaluation of Robotic Arm Rehabilitation in Stroke Patients: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Robotic Arm Rehabilitation in Stroke Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00333983).Phase NAResults postedn = 62NCT00333983
• Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 32NCT01692938
• Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 32NCT02365467
• Evaluation of Various Methods Used to Identify the Proximal Humerus Intraosseous Vascular Access Site: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Various Methods Used to Identify the Proximal Humerus Intraosseous Vascular Access Site: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 60NCT01742780
• EVEREST IIIndependent statistical analysis of EVEREST II, evaluating percutaneous mitral valve repair using the MitraClip implant in a high-risk registry of patients with mitral valve insufficiency and regurgitation.Phase NAResults postedn = 78NCT01940120

← All therapeutic areas